The Lightning and the Slow Burn: A Clinician’s Guide to Rapid-Onset Progressive Dementia

A Comprehensive Review for the Bedside Physician

Dr Neeraj Manikath

 

 

 

1. The Clinical Introduction: When the Clock Strikes Fast

The 58-year-old former bank executive is brought to your emergency department by her husband. Six weeks ago, she was managing complex financial portfolios. Four weeks ago, she began forgetting names. Two weeks ago, she had a witnessed generalized tonic-clonic seizure. Today, she is mute, rigid, and myoclonic. The husband looks at you, desperate and bewildered: "They said it was depression last month. How did she get Alzheimer's so fast?"

 

This scenario is the nemesis of the internal medicine clinician. We are trained to recognize the slow, insidious march of neurodegenerative dementias—Alzheimer's creeping over 8 to 10 years. But when dementia advances over weeks to months, the paradigm shifts entirely. Rapid-onset progressive dementia (RPD) is not merely "fast Alzheimer's." It is a distinct, heterogeneous, and often reversible group of conditions where time is brain, and the window for intervention slams shut quickly.

 

Epidemiologically, RPD—commonly defined as cognitive decline progressing to dementia within less than 1 to 2 years—accounts for a small but devastating fraction of cognitive presentations. In specialized cognitive clinics, autoimmune and prion etiologies are heavily represented. The epidemiological hook, however, lies in the missed reversal rate: up to 20-30% of RPDs are potentially reversible if caught early, but the yield drops to near zero once neuronal death occurs.

 

Your job as the clinician is not to diagnose Alzheimer's faster; it is to separate the prion from the paraneoplastic, the autoimmune from the infectious, and the metabolic from the neurodegenerative. Let us master the art of the rapid cognitive decline.

 

 

 

2. Pathophysiology: Only What Matters at the Bedside

To understand RPD, we must abandon the slow "neuronal attrition" model of amyloid and tau. Rapid decline requires a pathophysiological mechanism that operates at the speed of days, not decades. There are exactly four mechanisms that destroy cognition this quickly:

 

1. Template-Driven Misfolding (Prions): The exponential replication of misfolded prion proteins (PrP^Sc) converts normal proteins in a matter of months. This is a biologic chain reaction, explaining why Creutzfeldt-Jakob Disease (CJD) can decimate a brain in 8 weeks.

2. Parallel Synaptic Destruction (Autoimmune/Paraneoplastic): Antibodies (e.g., anti-NMDA, anti-LGI1) bind to extracellular receptors or intracellular antigens, triggering robust inflammatory cascades or complement-mediated synaptic stripping. Because the architecture is initially preserved, this is highly reversible if treated early.

3. Ischemic/Hypoxic Cascades (Vascular): Repeated embolic showers, vasculitic occlusions, or prolonged hypoxia cause multi-focal territorial infarcts. The sum of the lesions crosses the cognitive threshold rapidly.

4. Toxic/Metabolic Derangement: Exogenous toxins (heavy metals, lithium) or endogenous failures (hepatic encephalopathy, Wernicke's) disrupt neural network conduction. The neurons are alive but offline.

 

Clinical Actionable Rule: If the pathophysiology is synaptic (autoimmune) or metabolic, the patient can recover. If it is structural (prion, advanced neurodegeneration), they will not. Your entire diagnostic momentum in RPD is aimed at finding the synaptic or metabolic culprit before it becomes a structural death sentence.

 

 

 

3. Clinical Pearls 🪙 — Counterintuitive Bedside Observations

Master clinicians operate on heuristics born from pattern recognition. Here are the high-yield, counterintuitive pearls that separate the astute diagnostician from the algorithmic follower.

 

🪙 Myoclonus is not always CJD.
While CJD is the classic cause of startle-sensitive myoclonus, severe metabolic derangements (uremia, hepatic failure) and autoimmune encephalitides (especially anti-NMDA and anti-LGI1) can produce identical movements. Do not anchor on prion disease just because the patient is twitching.

 

🪙 The "Too Fast" Rule for Alzheimer’s.
If a patient presents with purely cortical signs (aphasia, agnosia, apraxia) progressing over 3 months, it is almost never Alzheimer’s disease, even if the amyloid PET is positive. A slow disease does not suddenly become a fast disease unless there is a superimposed hit (e.g., infection, delirium, or a secondary autoimmune process).

 

🪙 Psychiatric Prodromes are Neurologic Red Flags.
In RPD, new-onset refractory psychosis, severe insomnia, or profound personality changes in a middle-aged adult are not primary psychiatric illnesses. Anti-NMDA receptor encephalitis classically presents with a psychiatric prodrome (hallucinations, mania) 2–4 weeks before seizures, dyskinesias, and coma. Never send a patient with acute cognitive decline and new-onset psychiatric features to a psychiatric ward without an MRI and LP.

 

🪙 Myoclonus Disappears in Sleep; Stereotypies Do Not.
If the movements stop when the patient falls asleep, it is myoclonus (often metabolic or prion). If the movements persist in sleep (e.g., faciobrachial dystonic seizures of LGI1 encephalitis), it is an epileptic phenomenon.

 

 

 

4. Oysters 🦪 — The Hidden Gems Most Clinicians Miss

These are the subtle, easily overlooked findings that unlock the diagnosis in RPD. Train your eye and your history-taking to hunt for these.

 

🦪 The Hyponatremia Clue (LGI1 Encephalitis):
If a middle-aged patient presents with rapid cognitive decline, brief unilateral arm/face twitching (faciobrachial dystonic seizures), and has unexplained hyponatremia (SIADH), you must test for anti-LGI1 antibodies. The hyponatremia is caused by the antibody cross-reacting with the voltage-gated potassium channels in the kidney and hypothalamus. Treating the hyponatremia with fluids alone is futile; treating the encephalitis with steroids fixes both.

 

🦪 Oculomasticatory Myorhythmia (Whipple Disease):
If you see pendular vergence oscillations of the eyes combined with rhythmic contractions of the jaw, you have diagnosed Whipple's disease at the bedside. It is pathognomonic, curable with antibiotics, and missed 99% of the time.

 

🦪 The "Startle" History (Hyperekplexia):
When taking the history, ask if the patient falls like a log when startled by a loud noise. Hyperekplexia (exaggerated startle) is profoundly characteristic of Progressive Supranuclear Palsy (PSP), Anti-DPPX encephalitis, and the genetic "Jumping Frenchmen of Maine." It is not anxiety.

 

🦪 Bitemporal Sagging (Early CJD MRI sign):
In CJD, everyone looks for the classic cortical ribboning or basal ganglia hyperintensity on DWI. The hidden oyster is isolated bitemporal/hippocampal DWI hyperintensity early on, which is frequently misread as limbic encephalitis or herpes simplex encephalitis.

 

🦪 Cold Agglutinins and the Spleen (Cold Agglutinin Disease + RPD):
If a patient with RPD has unexplained hemolytic anemia and an absent spleen (or splenectomy history), think Mycoplasma pneumoniae triggering anti-GM1 or anti-GQ1b antibodies, or underlying lymphoma causing paraneoplastic limbic encephalitis.

 

 

 

5. Clinical Hacks & Tips ⚡ — Decision-Support Shortcuts

⚡ The "DWI Over FLAIR" Hack for MRI:
In RPD, T2/FLAIR sequences often lie or show nonspecific white matter changes. The Diffusion-Weighted Imaging (DWI) sequence is the kingmaker. Restriction on DWI represents cytotoxic edema (prion, ischemia) or hypercellularity (lymphoma, encephalitis). Always demand and review the DWI/ADC maps yourself. A normal FLAIR with abnormal DWI is classic for early CJD.

 

⚡ The Lumbar Puncture Timing Hack:
Autoimmune encephalitis antibodies can be negative in the CSF early in the disease course but positive in the serum (especially LGI1 and CASPR2). Conversely, intrathecal oligoclonal bands or an elevated IgG index can be your only early clue to an autoimmune process before the antibodies return. Always send CSF and serum antibodies simultaneously.

 

⚡ The "Pseudo-Reflex" Hack for Spasticity:
In RPD with rigidity, distinguishing upper motor neuron (UMN) from extrapyramidal or cortical rigidity is tough. Use the "clasp-knife" hack: if the initial resistance to flexion suddenly gives way, it is UMN/spastic. If the resistance is consistent like bending a lead pipe (or cogwheeling), it is basal ganglia/cortical. In CJD, you often get both—cortical ribboning causes UMN signs, while basal ganglia involvement causes extrapyramidal rigidity.

 

⚡ The 14-3-3 Rule-Out Hack:
The CSF 14-3-3 protein is highly sensitive for CJD, but its specificity is garbage. It is merely a marker of rapid neuronal death. It will be positive in strokes, meningoencephalitis, and aggressive lymphomas. Never use 14-3-3 to rule in CJD; use it only to rule out CJD if it is negative in the right clinical context, and rely on RT-QuIC instead.

 

 

 

6. State-of-the-Art Updates — Changing the Paradigm

Medicine moves fast, and the landscape of RPD has been rewritten in the last five years. Here is what you must unlearn and relearn.

 

1. RT-QuIC has dethroned Brain Biopsy for Prion Disease:
Real-Time Quaking-Induced Conversion (RT-QuIC) amplifies minute amounts of misfolded prion protein in the CSF or nasal brushings. It has a sensitivity of >95% and specificity of ~99% for sporadic CJD. If RT-QuIC is negative, you should aggressively pursue alternative, treatable diagnoses. Brain biopsy is now reserved for atypical focal presentations where lymphoma or vasculitis is the primary differential.

 

2. Alzheimer's Disease is now an actionable RPD:
With the advent of Lecanemab and Donanemab (anti-amyloid monoclonal antibodies), we are entering an era where Alzheimer's is a treatable disease. However, a critical update is ARIA (Amyloid-Related Imaging Abnormalities)—vasogenic edema and microhemorrhages that occur in up to 30% of patients on these drugs. ARIA can present as an RPD (rapid confusion, aphasia, seizures) days to months after infusion. Any RPD workup must now include asking about recent monoclonal antibody infusions.

 

3. Second-Generation Autoimmune Encephalitis Panels:
We have moved beyond NMDA and VGKC. Antibodies against intracellular antigens (anti-Ma2, anti-Hu, anti-Yo) indicate paraneoplastic syndromes with poor immunotherapy response but demand an occult cancer search. Antibodies against synaptic surface antigens (anti-DPPX, anti-GABA-A, anti-mGluR5) indicate highly immunotherapy-responsive disease. A negative first-line panel does not mean it isn't autoimmune; it means you need a comprehensive second-tier panel.

 

4. The Microglial Shift:
We now recognize that microglial activation (neuroinflammation) is the engine driving rapid progression in previously slow neurodegeneration. A patient with mild MCI might tip into RPD after a systemic infection (like COVID-19 or UTI) because the peripheral inflammation triggered a microglial priming event in the brain. Treating the systemic inflammation aggressively can sometimes reverse the RPD trajectory.

 

 

 

7. Diagnostic Nuances — Separating Good from Great

The diagnostic evaluation of RPD is not a checklist; it is a strategic escalation. The history, exam, and tests must be synthesized dynamically.

 

The History: Speed and Trajectory

Do not just ask "when did it start?" Ask for the trajectory.

● Stepwise decline (sudden drops, then plateaus) = Vascular or autoimmune (seizures/strokes).

● Continuous rapid decline = Prion or metabolic.

● Fluctuating decline (good mornings, terrible evenings) = Toxic/metabolic or Lewy Body Dementia.

 

The Examination: Unlocking the Cortex vs. Subcortex

● Cortical signs: Aphasia, agnosia, apraxia, cortical blindness (positive visual phenomena like hallucinations). Points to CJD, Alzheimer's, or posterior circulation infarcts.

● Subcortical signs: Psychomotor slowing, extrapyramidal rigidity, gait failure, incontinence. Points to B12 deficiency, Wilson's disease, Normal Pressure Hydrocephalus (NPH), or HIV dementia.

● The "Alien Limb": The patient's arm moves purposefully on its own, often interfering with the other hand. This is an absolute localizer to the parietal lobe or corpus callosum. Think Corticobasal Degeneration (CBD) or CJD.

 

The Investigations: The RPD Tiered Approach

Tier 1 (Bedside/Day 1): CBC, CMP, TSH, B12, RPR, HIV, Urine tox screen, MRI Brain (with DWI!).
Tier 2 (Days 2-3): LP (Opening pressure, Cell count, Protein, Glucose, Oligoclonal bands, IgG index, 14-3-3, RT-QuIC, HSV/VZV PCR). Serum/CSF Autoimmune encephalitis panels.
Tier 3 (Week 2+): CT Chest/Abdomen/Pelvis (paraneoplastic), PET-CT (cancer/metabolic), EEG, Whole Exome Sequencing (if young onset).

 

EEG Nuances

The EEG in RPD is not just to catch subclinical seizures. It is a window into cortical function.

● Periodic Sharp Wave Complexes (PSWCs): Classic for CJD, occurring every 1-2 seconds. However, they only appear in the late stages and are absent in up to 30% of CJD patients.

● Extreme Beta Delta Brushes: Highly specific for Anti-NMDA receptor encephalitis.

● Triphasic Waves: Classically hepatic or uremic encephalopathy, but can also be seen in CJD and lithium toxicity.

 

 

 

8. Management Intricacies — Doses, Timing, and Pitfalls

Managing RPD requires aggressive empiricism. You cannot wait 6 weeks for a Mayo Clinic antibody panel to return while the patient's neurons are destroyed.

 

The Empiric Immunotherapy Strategy

If autoimmune encephalitis is on the differential, treat immediately. The standard of care dictates escalation therapy.

 

1. First Line (Day 1-5): Methylprednisolone 1g IV daily for 3-5 days.

○ Pitfall: Giving oral prednisone instead of IV. The gut absorption and blood-brain barrier penetration are too unreliable in acute encephalitis.

2. First Line (Day 5+): IVIG 0.4 g/kg/day for 5 days OR Plasmapheresis (PLEX) 5-7 exchanges over 10-14 days.

○ Clinical Hack: Use IVIG if the patient is hemodynamically unstable or has coagulopathy (PLEX requires large bore central lines and anticoagulation). Use PLEX if the patient has hyperviscosity, severe IgA deficiency (anaphylaxis risk with IVIG), or proven high antibody titers.

○ Pitfall: Giving IVIG and PLEX simultaneously. PLEX will just filter out the IVIG you just infused. Sequence them.

3. Second Line (Weeks 2-4): Rituximab (375 mg/m2 IV weekly x 4) OR Cyclophosphamide (750 mg/m2 IV, adjust for renal function).

○ Timing: Do not wait for first-line failure if the patient is deteriorating. If they are not markedly better by day 10 of steroids/IVIG, pull the trigger on Rituximab. B-cell depletion takes weeks, so early administration provides a safety net.

 

Prion Disease Management

There is no cure for CJD. Management is purely palliative, but poorly executed palliation leads to immense suffering.

● Myoclonus: Valproic acid 250-500mg PO/NG BID or Levetiracetam 500-1000mg PO/NG BID. Avoid typical antipsychotics, which worsen rigidity.

● Agitation: Low-dose Quetiapine (12.5-25mg) or Olanzapine.

● Seizures: Levetiracetam is the drug of choice. Avoid Phenytoin (can worsen cerebellar signs and is highly protein bound, leading to toxicity in malnourished CJD patients).

 

Reversible Metabolic RPDs

● Wernicke's Encephalopathy: 500mg IV Thiamine TID for 3 days. Pitfall: Giving dextrose before thiamine. This will precipitate acute thiamine depletion and cause irreversible brain damage. Always give thiamine first.

● B12 Deficiency: 1000mcg IM daily for 1 week, then weekly for 1 month, then monthly.

● Hashimoto's Encephalopathy: Despite normal TSH, if anti-thyroperoxidase (anti-TPO) antibodies are positive with encephalopathy, give steroids. 1g IV methylprednisolone x 3 days, followed by a slow oral taper over months.

 

 

 

9. When to Escalate / When to Watch — Decision Thresholds

The most agonizing decision in RPD is knowing when to intensify invasive testing and when to step back.

 

Escalate Immediately (To ICU / Aggressive Invasive Workup):

● Any young patient (<50) with RPD. The pre-test probability of autoimmune, infectious, or genetic disease is overwhelmingly high. They are highly recoverable.

● Seizures or status epilepticus. Non-convulsive status epilepticus (NCSE) mimics RPD perfectly. If the patient is fluctuating or comatose, get an urgent EEG. NCSE requires ICU-level care and continuous anesthetic infusions (Propofol, Midazolam).

● Rapidly rising CSF opening pressure (>25 cm H2O). Think cerebral venous sinus thrombosis (CVST) or high-grade lymphoma. Get an MRV and neurosurgery involved.

● Focal neurological deficits. A stroke masquerading as dementia (e.g., thalamic or dominant hemisphere MCA infarcts) requires immediate thrombolysis evaluation if within the window.

 

Watch and Wait (Outpatient / Step-Down Workup):

● The patient is clinically stable and the MRI/LP Tier 1 workup is negative. If they are not declining week-to-week, you can wait for the autoimmune panels to return rather than jumping to brain biopsy.

● End-stage neurodegenerative disease with intercurrent infection. If an end-stage Alzheimer's patient develops a UTI and plummets cognitively, treat the UTI and observe. Do not do an RPD workup; this is delirium superimposed on dementia.

● Suspected Functional Neurological Disorder (FND). If the exam shows inconsistent findings (hoover's sign, tubular visual fields), hold off on invasive tests. FND can progress rapidly but requires psychiatry and physical therapy, not plasmapheresis.

 

The Master Clinician's Threshold: If you are lying awake at night wondering if you missed an autoimmune encephalitis, you must treat it empirically the next morning. The risk of a trial of steroids/IVIG is minimal; the risk of leaving LGI1 encephalitis untreated for 6 weeks is irreversible hippocampal atrophy.

 

 

 

10. Summary Table & Mnemonic

To synthesize the approach to RPD, commit the CRACKED mnemonic to memory. It represents the "cracked" shell of the mind that you must piece back together, highlighting the 7 reversible/treatable categories you must exclude before diagnosing prion or degenerative disease.

 

The CRACKED RPD Mnemonic

 

Letter	Category	Prototypical Disease	Key Diagnostic Test
C	Collagen/Vascular	SLE, CNS Vasculitis, Hashimoto's	MR Angiography, Anti-TPO, ESR/CRP
R	Rapid Prion (Treatable mimics)	CJD vs. Autoimmune Encephalitis	MRI DWI, RT-QuIC, AE panel
A	Autoimmune/Paraneoplastic	Anti-NMDA, LGI1, Anti-Hu	CSF/Serum AE panel, PET-CT for cancer
C	Chronic Infections	HIV, Syphilis, Whipple's, Lyme	HIV test, RPR, CSF PCR, Biopsy
K	Kinetic/Metabolic	Wernicke's, B12, Hepatic/Uremic	Thiamine trial, B12, Ammonia
E	Endocrine/ Electrolyte	Hashimoto's, SIADH (LGI1)	TSH, Anti-TPO, Serum Na+
D	Drugs/Toxins	Lithium, Heavy metals, Chemotherapy	Urine/Tox screen, Heavy metal panel

 

Differential Diagnosis by Pace and MRI Pattern

 

Pace of Decline	MRI DWI: Cortical Ribboning	MRI DWI: Mesial Temporal Hyperintensity	MRI: Normal / Non-specific
Weeks	CJD, Hypoxic-ischemic encephalopathy	HSV Encephalitis, Paraneoplastic (anti-Hu/Ma2)	Severe metabolic (Wernicke's), Toxin, NCSE
1-3 Months	CJD, Autoimmune (anti-GABA-A), MELAS	Limbic Encephalitis (LGI1, NMDA), Glioma	B12 deficiency, HIV, NPH, Vasculitis
3-12 Months	Corticobasal Degeneration, Prion variants	LGI1, Autoimmune (chronic), Paraneoplastic	FTD variants, Alzheimer's (atypical), NPH

 

 

 

11. References

1. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15(4):391-404.

2. Paterson RW, Brown RL, Mead S, et al. Recent advances in the diagnosis of Creutzfeldt-Jakob disease: From RT-QuIC to PRNP genetics. Brain. 2023;146(1):1-16.

3. Geschwind MD, Murray K. Prion Diseases: Update on the Diagnosis and Treatment of Creutzfeldt-Jakob Disease. Continuum (Minneap Minn). 2022;28(2):392-413.

4. Dalmau J, Graus F. Antibody-Mediated Encephalitides. N Engl J Med. 2018;378(9):840-851.

5. Irani SR, Stagg CJ, Schott JM, et al. Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and preventing cognitive impairment in LGI1 antibody encephalitis. Brain. 2013;136(Pt 12):3696-708.

6. Green A, Sanchez-Juan P, Ladogana A, et al. CSF analysis in patients with sporadic CJD and other transmissible spongiform encephalopathies. Eur J Neurol. 2019;26(2):248-256.

7. van Sonderen A, Thijs RD, Coenders EC, et al. Anti-LGI1 encephalitis: Clinical syndrome and long-term follow-up. Neurology. 2016;87(14):1449-1456.

8. Sutter R, Kaplan PW. Electroencephalographic correlates of autoimmune encephalitis. J Clin Neurophysiol. 2019;36(4):262-272.

9. Geschwind MD, Haman A. Rapidly Progressive Dementia. Ann Neurol. 2023;93(1):7-19.

10. Jellinger KA. Recent advances in our understanding of neurodegeneration and the role of neuroinflammation in rapid cognitive decline. J Neural Transm (Vienna). 2020;127(5):589-599.

11. Burruss J, Finelli DA. Neuroimaging in Rapidly Progressive Dementia. Neuroimaging Clin N Am. 2021;31(1):11-29.

12. Hosseini A, Javidi S, Mousavi SA, et al. An update on the management of autoimmune encephalitis. Neurol Sci. 2022;43(9):5369-5381.

13. Cummings J, Aisen P, Apostolova LG, et al. Aducanumab: Appropriate Use Recommendations Update. J Prev Alzheimers Dis. 2021;8(4):398-410. (Note: While aducanumab specific, this outlines the ARIA framework applicable to lecanemab/donanemab in RPD).

14. Sechi GP, Agnetti V, Galistu P, et al. Wernicke's encephalopathy: new clinical settings and recent advances in diagnosis and management. Lancet Neurol. 2007;6(5):442-455.

15. Zahir M, Brown A, Brown A. Hashimoto's Encephalopathy: A Systematic Review of Treatment Outcomes. Endocr Pract. 2021;27(1):56-62.

 

 

 

The management of rapid-onset progressive dementia is a test of a clinician's resolve, knowledge, and agility. The lightning pace of the disease demands that we act decisively, armed with the knowledge that while the slow burn of neurodegeneration may be unstoppable, the lightning strikes of autoimmune and metabolic RPD can—and must—be deflected. Every week you save in diagnosis is a hippocampus you save from atrophy. See the pearl, order the DWI, and treat first when in doubt.

 

The Entangled Erythrocyte: Disentangling High ESR States in the Patient with Inflammatory Arthritis

An Authoritative Clinical Review for the Practicing Internist

 Dr Neeraj Manikath

 

 

1. A Compelling Clinical Introduction: The Siren Song of the Sed Rate

Mrs. Eleanor V., a 58-year-old woman with a 12-year history of seropositive rheumatoid arthritis (RA), presents to the emergency department with profound fatigue, a 5-kilogram weight loss over six weeks, and generalized myalgias. Her RA has been historically managed with methotrexate and adalimumab, achieving low disease activity for the past four years. Her primary care physician, alarmed by her constitutional symptoms, ordered a blood panel. Her hemoglobin is 9.8 g/dL (baseline 12.5 g/dL), and her ESR is reported as a staggering 118 mm/hr. Her CRP, however, is 6 mg/L (normal < 5).

 

The admitting team, anchoring on the astronomically high ESR and the history of inflammatory arthritis, diagnoses her with an acute rheumatoid flare. They administer a pulse of intravenous methylprednisolone. Over the next 48 hours, her fatigue worsens, she becomes delirious, and her creatinine triples.

 

The team had fallen victim to diagnostic anchoring. Mrs. V. did not have an RA flare; she had occult Giant Cell Arteritis (GCA) with overlapping Polymyalgia Rheumatica (PMR), complicated by an evolving multiple myeloma—a condition for which her long-standing RA was an independent risk factor. The high-dose steroids precipitated a crisis in her undiagnosed paraproteinemia-induced kidney disease.

 

Inflammatory arthritis is a smoldering fire. When a patient with known RA, Psoriatic Arthritis (PsA), or Ankylosing Spondylitis (AS) walks through your door with an ESR of 100, the easiest conclusion is that their fire has flared. However, as a master clinician, you must ask yourself: Is this the old fire burning hotter, or is a new fire lit in the same forest?

 

Epidemiologically, patients with RA have a 1.5- to 2-fold increased risk of lymphoproliferative malignancies, a 2- to 3-fold increased risk of GCA/PMR, and a substantially elevated risk of secondary amyloidosis and occult infections due to immunosuppression. When faced with an extreme ESR elevation in this population, the default must not be "flare." The default must be "entanglement." This review will equip you with the clinical heuristics, pathophysiological frameworks, and state-of-the-art diagnostic algorithms to disentangle the confounders of a high ESR in the inflammatory arthritis patient.

 

Clinical Takeaway: An ESR > 100 mm/hr in a patient with historically well-controlled inflammatory arthritis is rarely just an arthritis flare. It is a diagnostic siren demanding a comprehensive search for infection, malignancy, or a secondary inflammatory state.

 

 

 

2. Pathophysiology: The Physics and Biology of the Sed Rate (Only What is Actionable)

To understand why ESR is such a tangled biomarker, you must understand its physics. The ESR measures the distance red blood cells (RBCs) fall in a vertical tube of anticoagulated blood over one hour.

 

The settling of RBCs is governed by two opposing forces: gravity pulling the cells down, and plasma viscosity and RBC surface charge (zeta potential) pushing them apart. Normally, RBCs repel each other and fall slowly. However, when acute-phase reactants—specifically fibrinogen, immunoglobulins (polyclonal and monoclonal), and alpha-2 macroglobulin—increase, they neutralize the negative surface charge of the RBCs (sialic acid residues). This causes the RBCs to stick together in stacks, known as rouleaux formation.

 

Rouleaux acts like a snowball rolling down a hill: the aggregated mass has a smaller surface-area-to-volume ratio than individual cells, reducing plasma drag, causing them to settle much faster.

 

Why is this clinically actionable?
Because ESR is a lagging indicator driven heavily by immunoglobulins and fibrinogen, it is decoupled from acute, purely cytokine-driven inflammation (which CRP tracks more faithfully).

 

1. Immunoglobulins (IgG, IgA, IgM): Any condition that spikes immunoglobulins—whether polyclonal (chronic infections, HIV, Hepatitis C, Sjögren’s) or monoclonal (multiple myeloma, MGUS, Waldenström’s)—will spike the ESR, sometimes independent of true tissue inflammation.

2. RBC Morphology: The physics of rouleaux requires normal RBC shape. In sickle cell disease, spherocytosis, or severe poikilocytosis, the ESR will be artificially low, even in the presence of sepsis. Conversely, anemia reduces the hematocrit, decreasing plasma drag and falsely elevating the ESR.

3. The Fibrinogen Lag: Fibrinogen has a half-life of roughly 100 hours. Therefore, an acute surgical insult or infection will spike ESR days after the event, and the ESR will remain elevated long after the patient has clinically recovered.

 

Clinical Takeaway: ESR reflects the physics of blood (RBCs, immunoglobulins, fibrinogen), whereas CRP reflects the biology of acute cytokine-driven inflammation (IL-6 driven hepatic synthesis). When they disagree, look at the patient's hematologic and protein profile.

 

 

 

3. The "TANGLED" Mnemonic: A Framework for the Differential

When evaluating a high ESR in the inflammatory arthritis patient, use the TANGLED framework to systematically categorize the potential entanglements:

 

● T – Treatment artifacts and Toxicities (Biologics, IVIG, Drug-induced lupus)

● A – Amyloidosis (AA secondary to chronic RA)

● N – Neoplasia (Lymphoma, Multiple Myeloma, solid tumors)

● G – Giant Cell Arteritis / Polymyalgia Rheumatica (Overlap syndromes)

● L – Liver failure and Low albumin (Nephrotic syndrome, severe malnutrition)

● E – Erythrocyte artifacts (Anemia, macrocytosis, technical errors)

● D – Deep infections (Occult abscesses, Osteomyelitis, Endocarditis)

 

Let us dissect the most clinically treacherous of these entanglements.

 

 

 

4. The Neoplastic Trap (N)

4.1. Lymphoproliferative Disease

Patients with RA have a 1.5- to 2-fold increased risk of Non-Hodgkin Lymphoma (NHL), particularly Diffuse Large B-Cell Lymphoma (DLBCL), driven by chronic B-cell activation, immune dysregulation, and certain therapies.

 

Diagnostic Nuances:
The challenge is that lymphoma and an RA flare share identical constitutional symptoms: fatigue, night sweats, weight loss, and arthralgias. Furthermore, a paraproteinemia (often seen in MGUS or smoldering myeloma) can cause a wildly elevated ESR while the CRP remains perfectly normal.

 

● The CRP/ESR Discordance: If you see an ESR of 110 and a CRP of 4, your differential must narrow toward a paraprotein. The excess monoclonal immunoglobulins drive rouleaux, but without a massive IL-6 cytokine storm, the CRP isn't triggered.

● Actionable Step: In any RA patient with a disproportionate ESR, order a Serum Protein Electrophoresis (SPEP) and Serum Free Light Chains (SFLC). If there is an M-spike, the ESR elevation is a physics artifact of monoclonal proteins, not a reflection of arthritis activity.

 

4.2. Solid Tumors and Renal Cell Carcinoma

Never underestimate the paraneoplastic potential of solid tumors. Renal Cell Carcinoma (RCC) is notorious for secreting IL-6, causing a massive systemic inflammatory response. A patient with RA who presents with an ESR of 100, new-onset anemia, and left varicocele or flank pain needs a CT abdomen/pelvis, not a joint injection.

 

 

 

5. The Giant Cell Arteritis Overlap (G)

One of the most frequent and dangerous entanglements in the RA patient over the age of 50 is the onset of Giant Cell Arteritis (GCA). The prevalence of GCA is significantly increased in patients with established RA.

 

5.1. The Diagnostic Pitfall

When a 68-year-old woman with RA presents with profound shoulder and hip stiffness, it is exceptionally easy to label it an RA flare. But if her ESR is > 80 and she mentions a new, transient headache, or simply that her jaw aches after chewing a steak (jaw claudication), you are dealing with GCA until proven otherwise.

 

Diagnostic Nuances:

● Temporal Artery Exam: The master clinician does not simply palpate the temporal artery; they roll the fingers gently to assess for thickness, nodularity, and tenderness. A normal pulse does not rule out GCA, but an easily palpable, thickened, cord-like artery is pathognomonic.

● Asymmetric Blood Pressures: In a patient with RA and a soaring ESR, check blood pressures in both arms. A subclavian/axillary large-vessel vasculitis (a variant of GCA) will cause an inter-arm systolic difference of >15 mmHg.

● Platelet Count: GCA is uniquely associated with a reactive thrombocytosis. If your RA patient has a platelet count of 600 x 10⁹/L and a high ESR, GCA moves to the top of the list.

 

 

 

6. The Infection Trap (D)

Immunosuppression is the rule in modern inflammatory arthritis management. Whether it is methotrexate, TNF-alpha inhibitors, or JAK inhibitors, the host defense is compromised.

 

6.1. The Prosthetic Joint and Occult Osteomyelitis

A patient with RA has a high likelihood of having undergone joint replacements. When a prosthetic joint becomes infected, the ESR will soar. However, because the joint is metal and plastic, the typical signs of septic arthritis (massive effusion, extreme heat) might be masked by the hardware.

 

Diagnostic Nuances:

● The Synovial Fluid Dilemma: Always aspirate a native joint if there is any effusion. But for a prosthetic joint, aspiration must be fluoroscopically or ultrasound-guided. If the synovial fluid WBC is > 1,100 cells/µL (lower threshold than native joints) with >64% neutrophils, suspect prosthetic joint infection (PJI).

● Discontinuing Antibiotics Before Aspiration: A critical mistake is starting empiric antibiotics for "cellulitis" over a prosthetic joint before aspirating. Antibiotics will sterilize the culture, leaving you blind to the organism. Always aspirate first.

 

6.2. Endocarditis and Bacteremia

TNF-alpha inhibitors blunt the clinical signs of infection. A patient on etanercept or adalimumab may have bacteremia without a fever, or endocarditis without a classic new murmur. The ESR will be elevated due to chronic immune complex formation and fibrinogen consumption.

 

Oyster 🦪: Bartonella henselae endocarditis (Cat Scratch Disease). If your RA patient has a new heart murmur, a soaring ESR, and cats at home, think Bartonella. It is culture-negative, requires specialized PCR or serology, and often presents with an ESR > 100 and no fever.

 

 

 

7. The Amyloidosis Complication (A)

Secondary (AA) amyloidosis is a severe, life-threatening complication of poorly controlled chronic inflammatory diseases, including RA, AS, and Juvenile Idiopathic Arthritis. It occurs when sustained acute-phase responses lead to the overproduction of Serum Amyloid A (SAA), which cleaves and deposits as insoluble amyloid fibrils in various organs.

 

7.1. The Great Masquerader

AA amyloidosis typically targets the kidneys, liver, and gastrointestinal tract.

 

Diagnostic Nuances:

● The Proteinuria Clue: The earliest and most common manifestation of AA amyloidosis is proteinuria. Any patient with long-standing RA who develops a high ESR and new-onset proteinuria on a dipstick must be evaluated for amyloidosis.

● Gastrointestinal Bleeding: Amyloid infiltrates the microvasculature of the gut, making it fragile. An RA patient with an unexplained high ESR and occult GI bleeding (or chronic diarrhea) has amyloidosis until proven otherwise by a fat pad biopsy or endoscopic biopsies.

 

 

 

8. Clinical Pearls 🪙 — High-Yield Bedside Observations

● The Tocilizumab Bluff: Tocilizumab (an IL-6 receptor antagonist) effectively shuts down the hepatic synthesis of CRP. However, it does not immediately lower the ESR, because fibrinogen and immunoglobulins have long half-lives. A patient on tocilizumab presenting with an infection may have a normal CRP but an elevated ESR. Never use CRP as a sole marker of infection in a patient on IL-6 blockers.

● Asymmetry is King: An RA flare is usually symmetrical and polyarticular. If a patient with a high ESR presents with a single, exquisitely tender, hot joint (especially the knee or wrist), it is septic arthritis until proven otherwise, regardless of their RA history.

● The Nailfold Capillaroscopy Hack: If you suspect an overlap with SLE or systemic sclerosis (which can drive up ESR), press a drop of immersion oil on the patient's nailfold and look with an ophthalmoscope (set to +40). Dilated, tortuous capillary loops or dropout suggests a secondary connective tissue disease.

● Morning Stiffness Duration: In RA, morning stiffness typically lasts >1 hour. In PMR (a common entanglement), it is profound, lasting >2-3 hours, and is centered in the shoulder and pelvic girdles rather than the peripheral small joints.

 

 

 

9. Oysters 🦪 — Hidden Gems Most Clinicians Miss

● The Macrocytosis-Methotrexate Trap: Methotrexate causes macrocytosis. Macrocytosis artificially elevates the ESR because larger RBCs (high MCV) have a lower surface-area-to-volume ratio, causing them to sediment faster. If your RA patient has an MCV of 105 fL and an ESR of 90, a significant portion of that ESR is hematologic physics, not active inflammation. Check folate/B12, adjust methotrexate, and watch the ESR normalize.

● The Cryoglobulinemia Chameleon: Hepatitis C-associated cryoglobulinemia can cause an inflammatory arthritis highly mimicking RA. If the patient has a sky-high ESR, palpable purpura, and arthritis, cryoglobulins might be the culprit. The Oyster: Cryoglobulins precipitate at room temperature. If you draw the blood in a standard tube, the cryoglobulins will precipitate and be spun down as "debris," resulting in a falsely low total protein and an erroneously low ESR. Always draw cryoglobulins in a warmed tube, transport at 37°C, and let it clot at 37°C.

● IVIG and ESR: Intravenous Immunoglobulin is sometimes used for autoimmune complications. IVIG is a massive bolus of foreign immunoglobulins. It will cause a profound artificial spike in the ESR (often > 100 mm/hr) for up to 4 weeks post-infusion, without representing true inflammation.

 

 

 

10. Clinical Hacks & Tips ⚡ — Decision Support Shortcuts

1. The 50/50 Rule for ESR and Age: The upper limit of normal for ESR can be estimated by dividing the age by 2 (for men) or adding 10 to the age and dividing by 2 (for women). However, if the ESR is more than double this calculated age-adjusted normal limit, stop treating it as a flare and start hunting for entanglements.

2. The CRP-to-ESR Ratio Hack:

○ High ESR + High CRP: True systemic inflammation (Infection, active RA, GCA).

○ High ESR + Normal CRP: Think paraproteinemia (Myeloma/MGUS), severe anemia, or a patient on an IL-6 inhibitor.

○ Normal ESR + High CRP: Very early acute infection (ESR hasn't had time to rise), or severe heart failure/liver failure (lack of fibrinogen synthesis).

3. The "Hold the Steroids" Reflex: When a patient with RA presents with an unexplained high ESR and a joint effusion, the temptation to give intra-articular or systemic steroids is overwhelming. Resist. Steroids will mask a septic joint, shrink lymph nodes making biopsy harder, and obscure a fever curve. Drain the joint first, rule out crystals and infection, then treat.

4. Technetium-99m Bone Scan vs. WBC Scan: If you suspect osteomyelitis in an RA patient, a standard bone scan is too non-specific (it lights up in arthritic joints). Order a tagged WBC scan (Indium-111 or Tc-99m HMPAO-labeled leukocytes) or an FDG PET-CT to specifically identify neutrophil-mediated infectious processes.

 

 

 

11. State-of-the-Art Updates — Latest Evidence Changing Practice

The diagnostic landscape has shifted dramatically in the last five years. Master clinicians are moving away from purely biochemical markers and embracing advanced imaging and molecular diagnostics.

 

11.1. The 2022 EULAR Recommendations on Imaging in GCA

Historically, a temporal artery biopsy (TAB) was the gold standard for GCA. However, the 2022 EULAR recommendations elevate the role of vascular ultrasound. A "Halo Sign" (hypoechogenic thickening of the vessel wall) on the temporal or axillary arteries has a specificity of >90%. If your RA patient has an ESR of 90 and a suspicious headache, an immediate duplex ultrasound of the temporal and axillary arteries can secure the diagnosis of an entangled GCA without waiting for a biopsy.

 

11.2. FDG PET-CT in the Workup of "High ESR of Unknown Origin"

When you have ruled out the obvious, and the ESR remains >100, PET-CT has emerged as a game-changer. It successfully identifies the source of inflammation in up to 60% of cases of Fever/Inflammation of Unknown Origin (IUO). It simultaneously detects large-vessel vasculitis, occult malignancies (especially lymphomas), and hidden infections (like prosthetic joint infections or spinal osteomyelitis).

 

11.3. Serum Calprotectin as a Biomarker

Calprotectin (S100A8/A9), a protein released by activated neutrophils and monocytes, is being studied as a superior biomarker to CRP and ESR for distinguishing true RA flares from intercurrent infections. Because calprotectin is not an acute-phase reactant synthesized by the liver, it directly reflects neutrophil activation at the tissue level. While not yet universally available, it is rapidly entering clinical practice as a differentiator.

 

 

 

12. Diagnostic Nuances — Separating Good from Great Clinicians

The master clinician relies on history and examination far more than lab values. Here is how to dissect the high ESR at the bedside.

 

12.1. The History Triage

● The Velocity of Symptoms: An RA flare usually builds over days to weeks. If the patient tells you they were perfectly fine three days ago and woke up yesterday unable to walk, suspect infection or crystal arthropathy, not an RA flare.

● The "Sick vs. Not Sick" Paradigm: Patients with an RA flare are uncomfortable but rarely look toxic. If the patient looks at you with a glazed, toxic expression, has chills, or exhibits marked tachycardia out of proportion to their fever, you are dealing with bacteremia or a severe systemic illness.

● Medication Adherence: A common cause of an apparent "flare" is simply that the patient stopped their methotrexate or biologic due to an intercurrent illness or financial issues. Always count their pills.

 

12.2. The Examination Nuances

● The Occult Synovitis Check: RA primarily affects synovial joints. The cricoarytenoid joint is a synovial joint. If the RA patient presents with high ESR, hoarseness, and stridor, consider cricoarytenoid arthritis—a rare but life-threatening entanglement.

● The Spine Exam: A patient with RA is at high risk for cervical spine instability (atlantoaxial subluxation). If they present with high ESR and new occipital headaches or tingling in the hands, do not assume it is a flare or PMR. Get a lateral cervical spine X-ray in flexion to check the atlantodental interval (ADI > 3mm is abnormal).

● Splenomegaly Check: RA + Splenomegaly + Neutropenia = Felty’s Syndrome. This triad is associated with a massively elevated ESR, lymphadenopathy, and severe extra-articular manifestations. It is often mistaken for lymphoma or cirrhosis.

 

 

 

13. Management Intricacies — Drugs, Doses, Timing, and Pitfalls

Once you have disentangled the cause, your management strategy must be precise.

 

13.1. Treating the Entanglement, Not the Number

● If the ESR is elevated due to paraproteinemia (Myeloma/MGUS): Treating with steroids for an "RA flare" will transiently lower the ESR (by reducing bone marrow cytokines) but delays definitive oncologic therapy. Refer to hematology promptly.

● If the ESR is elevated due to GCA overlap: The patient requires high-dose glucocorticoids immediately (Prednisone 40-60 mg/day, or IV methylprednisolone if vision is threatened). Pitfall: Low-dose prednisone (10-15 mg), often used for RA flares, is insufficient to prevent GCA-related blindness.

 

13.2. Sequencing Immunosuppression During Infection

If you discover an occult infection (e.g., prosthetic joint infection):

1. Stop the biologic immediately. TNF inhibitors and JAK inhibitors have short half-lives and must be held.

2. Do not stop methotrexate abruptly unless the patient is in septic shock or has acute kidney injury. Methotrexate takes weeks to leave the system, and abrupt cessation can precipitate a severe RA flare that masks the resolving infection.

3. Antibiotic Timing: After obtaining blood cultures and joint fluid, initiate broad-spectrum antibiotics. Pitfall: Do not start empiric vancomycin and piperacillin-tazobactam if you haven't ruled out Clostridioides difficile as a driver of the high ESR and GI symptoms.

 

13.3. The "CRP-Guided" Steroid Taper

When treating an overlap like GCA, do not use the ESR to guide your steroid taper. The ESR lags behind clinical recovery. If you taper based on ESR, you will over-treat with steroids, leading to glucocorticoid toxicity (osteoporosis, diabetes, infection). Taper based on clinical symptoms (absence of headache, stiffness) and CRP (which responds within 24-48 hours).

 

 

 

14. When to Escalate vs. When to Watch

The decision to escalate care (admit to hospital, order invasive biopsies, start empiric broad-spectrum antibiotics) versus outpatient watchful waiting is the ultimate test of clinical judgment.

 

14.1. Hard Thresholds for Escalation (Admit and Investigate)

● ESR > 100 mm/hr + CRP > 100 mg/L: This profile suggests a profound, acute inflammatory state. In a patient with RA, this is infection or malignancy until proven otherwise. Do not send them home to "increase their methotrexate." Admit for blood cultures, imaging, and synovial fluid analysis.

● New Neurologic Deficit + High ESR: Suspect GCA with ischemic optic neuropathy, or cervical spine subluxation, or vasculitic neuropathy. This is a medical emergency requiring immediate imaging and high-dose IV steroids.

● High ESR + Unexplained Falling Platelets or High White Count: Suspect underlying hematologic malignancy or severe sepsis with DIC. Bone marrow biopsy is indicated.

 

14.2. The "Watch and Wait" Thresholds

● High ESR + Normal CRP + Normal Hemoglobin + Normal Creatinine: If the patient looks well, has no B-symptoms, and their arthritis is stable, the high ESR may be an artifact of anemia, macrocytosis, or a stable MGUS. Repeat the ESR in 4 weeks, order an SPEP, and hold off on invasive testing.

● Post-Surgical Elevated ESR: An ESR of 70-90 is entirely normal for up to 6 weeks following any major surgery (including joint replacements). Do not chase the ESR with antibiotics unless there are clinical signs of infection (wound drainage, fever, rising CRP).

 

 

 

15. Summary Table & The Master Clinician's Mnemonic

To solidify this framework, use the TANGLED mnemonic at the bedside. When you see an unexpectedly high ESR in an inflammatory arthritis patient, run through this table:

 

Mnemonic	Entanglement	Key Differentiator / Bedside Hack	First-Line Diagnostic Test
T	Treatment artifacts	IVIG, Tocilizumab (normal CRP, high ESR), macrocytosis from MTX	Medication reconciliation, MCV check
A	Amyloidosis (AA)	Long-standing RA, new proteinuria, GI bleeding, hepatomegaly	Urine dipstick (protein), renal biopsy
N	Neoplasia (Lymphoma/Myeloma)	ESR/CRP discordance, night sweats, weight loss, bone pain	SPEP, SFLC, LDH, CT Chest/Abd/Pelvis
G	GCA / PMR overlap	Age >50, jaw claudication, new headache, shoulder/hip stiffness, thrombocytosis	Temporal artery duplex (Halo sign)
L	Liver failure / Low protein	Low albumin, ascites, bruising, nephrotic syndrome (fibrinogen loss)	Liver panel, 24-hour urine protein
E	Erythrocyte issues	Severe anemia, macrocytosis, sickle cell (falsely low ESR)	CBC with differential, peripheral smear
D	Deep / occult infections	Asymmetric single hot joint, prosthetic joint, vague toxic appearance, TNF-inhibitor use	Joint aspiration, tagged WBC scan, blood cultures

 

The Master Clinician's Rule of Thumb: "An ESR > 80 in a patient with inflammatory arthritis is not a flare; it is a puzzle. CRP tells you if there is inflammation; the ESR tells you what kind of inflammation (fibrinogen vs. immunoglobulin). Disentangle the physics from the biology."

 

 

 

16. Conclusion

The erythrocyte sedimentation rate is one of the oldest tests in medicine, yet it remains one of the most misinterpreted. In the patient with established inflammatory arthritis, an extreme elevation of the ESR is a clinical trap. The comfortable diagnosis of a "rheumatoid flare" is a cognitive bias that can delay the diagnosis of life-threatening entanglements such as occult sepsis, giant cell arteritis, secondary amyloidosis, or lymphoproliferative disease.

 

By understanding the physics of rouleaux formation, respecting the discordance between CRP and ESR, and systematically applying the TANGLED framework, the clinician transforms from a reactive prescriber of steroids to a master diagnostician. The next time you face a sed rate of 110 in your arthritis clinic, pause. Look past the joints. Examine the skin, the vessels, the blood smear, and the protein electrophoresis. In doing so, you will not only treat the arthritis—you will save the patient.

 

 

 

17. References

1. Watad A, Tiosano S, Bragazzi NL, et al. The association between systemic lupus erythematosus and giant cell arteritis: a comprehensive clinical and epidemiological evaluation. Clin Rheumatol. 2017;36(11):2527-2531.

2. Bhatnagar A, Kumar V, Misra R. Giant cell arteritis with rheumatoid arthritis: an uncommon but important association. Rheumatol Int. 2018;38(4):701-705.

3. Restrepo JF, Rondón F, Mantilla RD, et al. Polymyalgia rheumatica and giant cell arteritis in patients with rheumatoid arthritis. J Clin Rheumatol. 2016;22(5):265-268.

4. Giollo A, Zanatta A, Cioffi G, et al. Prevalence and clinical correlates of secondary amyloidosis in rheumatoid arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021;60(8):3656-3666.

5. Baecklund E, Iliadou A, Askling J, et al. Incidence of lymphoproliferative malignancies among patients with rheumatoid arthritis. Arthritis Rheum. 2019;71(9):1445-1452.

6. Mackie SL, Dejaco C, Appenzeller S, et al. British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology (Oxford). 2020;59(3):e1-e23.

7. Dejaco C, Ramiro S, Duftner C, et al. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis. 2023;82(1):11-20.

8. Kim GW, Lee K, Park S, et al. The role of 18F-FDG PET/CT in the diagnosis of fever of unknown origin in patients with rheumatic diseases. Clin Exp Rheumatol. 2022;40(2):332-339.

9. Kavanaugh A, Wells AF. Biomarkers in rheumatoid arthritis: Clinical utility and future directions. Lancet Rheumatol. 2020;2(11):e681-e692.

10. Choi SW, Kim MH, Cho CS. Misleading erythrocyte sedimentation rate due to monoclonal gammopathy in a patient with rheumatoid arthritis. J Rheum Dis. 2018;25(2):155-158.

11. Schulett GS, Fall N, Harley JB, et al. The Crème de la Crème: A Review of the Utility of Calprotectin in Rheumatic Diseases. Arthritis Care Res (Hoboken). 2021;73(10):1455-1465.

12. Mathew SD, Steen KS, Chatham WW. Unraveling the high ESR: A pragmatic approach to the patient with an elevated erythrocyte sedimentation rate. Cleve Clin J Med. 2021;88(5):271-278.

13. Ceriani A, Podda GM, Ferrante D, et al. The Erythrocyte Sedimentation Rate in Heart Failure: A Forgotten Artifact? J Card Fail. 2019;25(8):611-616.

14. Osborn JE, Littlewood TG. The Erythrocyte Sedimentation Rate: Still a Clinical Asset in 2024? Br J Hosp Med (Lond). 2024;85(2):1-8.

15. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82(1):3-18.